Imricor Med SYS Secures FDA Pediatric Clearances for Radiation Free Heart Procedures

Imricor secures dual FDA clearances opening pediatric market for radiation-free heart procedures

Imricor Medical Systems (ASX: IMR) has received FDA 510(k) clearance to expand the labelling of both its NorthStar system and its Vision-MR Diagnostic Catheter to include pediatric use. The dual clearances allow the company to market both devices for patients of any age, including children and young adults.

The approvals open access to more than 250 children’s hospitals across the United States. They also establish a new commercial market for the company: diagnostic interventions built off NorthStar, described as “the world’s first and only MR-native 3D iMR mapping and guidance system.”

Pediatric patients who may benefit include those born with congenital heart defects who require several cardiac catheterisations at a young age. Across both adult and children’s hospitals in the US, over 250,000 diagnostic right and left heart catheterisations are performed annually.

Why these clearances matter to Imricor’s commercialisation strategy

Imricor believes the pediatric market represents “an attractive early commercial channel” for NorthStar and the Vision-MR Diagnostic Catheter, ahead of broader US adoption of the company’s full electrophysiology (EP) platform in adult hospitals.

Children’s hospitals often have a strong interest in reducing radiation exposure and the use of contrast dyes for their patients, making iMR a natural fit. Young people are more sensitive to ionising x-ray radiation exposure, and iMR procedures eliminate all procedure-related x-rays for children who require multiple catheterisations early in life.

Diagnostic interventions represent a new market for Imricor, giving investors a fresh revenue channel that leverages the existing NorthStar platform.

NorthStar’s adult FDA clearance, secured in January 2026, established the 510(k) foundation that made the subsequent pediatric label expansion possible, with the platform’s software-driven model also creating recurring consumable revenue potential at each installed site.

Imricor’s Chair and CEO, Steve Wedan, framed the clearances as a reflection of the company’s commitment to all patient groups.

Steve Wedan, Chair and CEO

“We care about children, and we don’t shy away from delivering our products to all patient segments who can benefit from radiation-free iMR procedures.”

“Having experienced first-hand, the pediatric use of products I personally developed throughout my career, I can say there is something particularly rewarding about providing technology to help infants and young children. Changing the world of interventional medicine for doctors and patients means changing it for all doctors and all patients.”

Understanding interventional MR (iMR) and why radiation matters

Interventional magnetic resonance (iMR) is a way of performing cardiac procedures under real-time MR guidance rather than under x-ray guidance. The distinction carries practical significance for both patients and hospitals.

Traditionally, a procedure has involved an MRI scan followed by a separate intervention in an X-ray lab. iMR allows both steps to be completed within the MRI environment, which Imricor says delivers “significant time and cost savings to hospitals.”

Radiation matters especially for children. Young people are more sensitive to ionising x-ray radiation exposure, and eliminating procedure-related x-rays is a meaningful clinical benefit for those facing repeated catheterisations.

NorthStar sits at the centre of this approach as an MR-native 3D mapping and guidance system used to navigate iMR procedures. The workflow contrast is straightforward:

1. Traditional: MRI scan → transfer → X-ray lab intervention (radiation exposure)

2. iMR with NorthStar: diagnosis and intervention performed in the MRI (no procedure x-rays)

For investors, reducing procedure steps and radiation exposure presents a clear value proposition that may support hospital adoption.

The path so far and what comes next

The dual clearances follow a defined sequence of regulatory milestones over the past year. During the FDA review process, Imricor decided to also submit the Vision-MR Diagnostic Catheter for pediatric labelling, providing a more complete set of pediatric iMR devices.

• January 2026: NorthStar received FDA clearance for use in adult patients

• April 2026: NorthStar submitted for pediatric labelling expansion

• During review: Imricor decided to also submit the Vision-MR Diagnostic Catheter for pediatric labelling

• 2 July 2026: Both devices received FDA pediatric clearance

An outstanding catalyst remains. The Vision-MR Diagnostic Catheter provides an actively-tracked tool in the iMR lab for diagnostic electrophysiological applications, “once the Advantage-MR EP Recorder/Stimulator is cleared by the FDA.” That clearance has not yet occurred.

The Advantage-MR FDA submission was filed in February 2026 under the 510(k) pathway, which typically offers shorter review timelines than a de novo application, with the system already carrying approvals in Europe, Saudi Arabia, and New Zealand ahead of its US clearance decision.

Imricor describes the pediatric clearances as “another important step in the Company’s U.S. commercialization strategy.” For context, the company’s products are already approved in the European Union, the Kingdom of Saudi Arabia, and New Zealand, while NorthStar is approved in the US. These are existing approvals rather than new developments, but they frame the broader regulatory footprint against which the latest pediatric clearances sit.

Don’t Miss the Next Healthcare Breakthrough on ASX

Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ investors already staying ahead of the market. Click the “Free Alerts” button at Big News Blast to receive real-time coverage the moment market-moving announcements drop.